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News and topics
Clinical applications of multiparametric MRI within the prostate cancer
diagnostic pathway
Interest in integrating MRI into the prostate (CaP) cancer
diagnostic pathway seems to be gaining ground [1]. Mul-
tiparametric (mp)MRI combines diffusion-weighted, dy-
namic contrast enhanced sequences or MR spectroscopy
with conventional T2-weighted sequences. This has resulted
in accuracy rates for the detection of clinically important
CaP that compare favorably with established tests, such as
X-ray mammography, for the detection of breast cancer
[1,2]. However, its exact clinical utility remains the subject
of legitimate professional disagreement. In this commen-
tary, we attempt to highlight the areas in which mpMRI may
have a role in improving the diagnosis and management of
CaP.
Multiparametric MRI in response to a negative first
biopsy
The main reason why the current diagnostic pathway for
CaP remains suboptimal is that the current standard, trans-
rectal ultrasound (TRUS) guided biopsy, is conducted
‘blind’ to the cancer location within the prostate. Men who
enter the current CaP diagnostic pathway on the basis of an
elevated serum prostatic specific antigen (PSA) level have a
1 in 4 chance of testing positive on TRUS guided biopsy.
More men, therefore, are subjected to TRUS guided biop-
sies than is probably necessary. This renders CaP diagnosis
a health state that is largely determined by chance. In fact,
it is slightly worse. Cancers, in the anterior prostate, apex,
and midline are either undersampled or never sampled,
resulting in clinically significant cancers going undetected
[3,4].
Because of this diagnostic strategy, many men are falsely
reassured that they are free of clinically significant cancer
when they are not. By using mpMRI to assess the risk status
of men with a previous negative biopsy, biopsies can be
targeted to visible MR lesions [5]. When this strategy has
been used, almost two-thirds (59%) of men with 2 or more
previous negative TRUS biopsies have been diagnosed with
cancer [6].
Multiparametric MRI as a triage test for men at risk
The recent attribution of a grade D by the U.S. Preven-
tive Services Task Force against PSA screening (in other
words of ‘moderate or high certainty that the service has no
net benefit or that the harm outweighs the benefits’) would
have us believe that PSA is not fit for the purpose [7].
However, it may be that the application of the verification
test that follows PSA requires scrutiny rather than rejection
of PSA screening altogether. In introducing imaging earlier
in the diagnostic pathway, before TRUS guided biopsy, in
those men with an elevated serum PSA or other risk factors,
urologists would conform to the practice adopted by clini-
cians treating other solid organ cancers [8].
For example, screening X-ray mammograms and breast
MRI scans performed for ‘at-risk’ women are scored ac-
cording to the Breast Imaging-Reporting and Data System
(BI-RADS) [9,10]. Scored between 0 and 5 according to the
likelihood that cancer is present, this reporting system was
developed by a consensus group endorsed by the American
College of Radiology to standardize and quality control the
reporting of breast imaging. Those with an equivocal score
of 3 would be recommended to have further follow-up
within a few months, while a score of at 4 or 5 denotes
suspicion for malignancy warranting biopsy directed to-
wards the area of suspicion. It would appear feasible for the
uro-oncology community to adopt the same approach, with
fewer and better image-targeted biopsies performed in men
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with a positive mpMRI [11,12]. In those with an equivocal
mpMRI, PSA surveillance or standard TRUS guided biopsy
would be recommended, while scores of 2 and below may
warrant no further follow-up, depending on individual pa-
tient and clinician preference.
One of the key attributes of modern imaging platforms in
cancer diagnosis is that the result correlates closely with
tumor burden. Multiparametric MRI has reduced sensitivity
for low grade, low-volume disease and, therefore, may sys-
tematically overlook clinically insignificant disease. If this
proves to be the case, its application as a triage test before
prostate biopsy might significantly address the problem of
overdiagnosis that is associated with the current diagnostic
pathway. Evidence is starting to accumulate that mpMRI
may be sensitive to tumor grade as well as tumor volume
[13–17], resulting in a high negative predictive value for
ruling out clinically significant disease [18]. This strategy
would reduce the incidence of treatment-related harm en-
countered by overdiagnosis of low-risk disease—the main
reason that the U.S.A. task force recommended against the
use of PSA screening.
Cancer localization on multiparametric MRI
Approximately one-third of patients undergoing active
surveillance have upgrading of disease on serial TRUS
guided biopsies [19,20]. In some men, this change is related
to true disease progression. However, in others it reflects the
inadequacy of a sampling biopsy technique to provide con-
sistent serial information on a patient’s pathologic status. As
an alternative, if mpMRI can accurately detect, localize, and
characterize tumors, we have the opportunity to monitor a
true and visible change in a lesion over time. There is
evidence that mpMRI can act as an accurate monitoring tool
for CaP progression in those men undergoing active sur-
veillance [21].
Accurate cancer localization may also aid the optimal
balance between oncologic outcome and genitourinary and
rectal side effects in nerve-sparing radical prostatectomy
[22] and dose escalation to the index lesion in radiotherapy
[23]. Novel experimental strategies to selectively treat the
cancer alone also rely on imaging. For instance, real-time
mpMRI has been used to direct focal treatments with laser
in Phase I/II trials [24].
Future studies
Despite agreement across the uro-radiology community
that mpMRI has a potential future in the standard diagnostic
pathway for CaP, differences in current conduct, interpre-
tation, and reporting of mpMRI renders reliable comparison
of research studies difficult [25,26]. This is currently an
impediment to widespread and effective adoption of this
technique. However, there are signs of change. Consensus
now exists on the minimal and optimal imaging standards
for mpMRI [25], and clinical practice guidelines have re-
cently been produced [27].
Once agreed, standardized mpMRI protocols and report-
ing schemes will require validation within prospective stud-
ies that evaluate the ability of mpMRI to detect, localize,
and characterize CaP against an appropriate reference stan-
dard. Such a trial is due to start imminently (http://clinical-
trials.gov NCT01292291).
Targeting of biopsies to lesions identified on mpMRI is
already in clinical use in a number of centers, but the
techniques adopted are varied. Some groups use ‘cognitive’
registration of the results of the mpMRI to target biopsies on
TRUS or transperineal prostate biopsies [28]. Prostate dis-
tortion and poor interpretation of imaging are potential
limitations. Other groups are evaluating ‘in-bore’ targeting
of lesions within the MR scanner, and have demonstrated
improved cancer detection rates [5,6], and risk stratification
of disease [29], compared with standard TRUS biopsies.
However, this technique carries a high burden on imaging
resources and time, and usually requires a general anes-
thetic. An alternative approach is to register MR images
onto an ultrasound platform, to allow real-time targeting of
lesions in the theater or out-patient clinical setting [11]. The
key to accuracy of this technique is in the development of
‘nonrigid’ registration that allows for movement and distor-
tion between prostate images. Such techniques are under
evaluation [30,31].
Long-term cost-of-care evaluation of integrating mpMRI
into the diagnostic pathway is difficult to model, as many
assumptions need to be incorporated. While transfer of costs
to other sectors of the health care community is guaranteed,
the impact on costs-of-care is more difficult to assume. If a
new test, such as mpMRI, could deliver fewer biopsies,
better biopsies, better risk stratification, more appropriate
treatment allocation, fewer diagnoses, and fewer men
treated overall, we might have a test that could impart
significant cost savings over decades. Moreover, the capital
expenditure has already been made in many parts of the
world as appropriate MR scanners are already in place. The
challenge will be to use the existing MRI facilities more
effectively and to refine the optimal sequences for prostate
so that scan time is minimized. Development of a healthcare
economic model to evaluate cost-effectiveness will be re-
quired before further conclusions can be drawn about the
potential long-term cost-savings of this strategy.
The integration of mpMRI within the diagnostic path-
way for CaP has been embraced for some time by a
number of centers in the world. There is likely to be
further dissemination once practice guidelines start mak-
ing recommendations based on good evidence—some-
thing that we shall see in the next couple of years.
Clinicians involved in CaP diagnosis and staging should
take this opportunity to begin to formulate good working
relationships with uro-radiologists. This is going to be
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the key partnership of the future that will result in better
care for men at risk.
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